Pfizer Pregabalin Approved For Marketing In Europe; FDA Review Continues
This article was originally published in The Pink Sheet Daily
The Neurontin follow-on is approved in the EU for neuropathic pain and as add-on therapy for partial seizures in patients with epilepsy. FDA's user fee deadline for pregabalin (Lyrica) is Oct. 30; Neurontin (gabapentin) generics could hit the market prior to pregabalin's approval.
You may also be interested in...
Pfizer's $430 mil. Neurontin off-label promotion settlement is the equivalent of about nine weeks of U.S. sales of the anti-epileptic brand
Ivax receives full ANDA approval for low dose tablet formulations of gabapentin. Teva licenses Alpharma's generic exclusivity for capsule form and higher dose tablets.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.